| Axon ID |
Name |
Description |
From price |
|
1128
|
Erlotinib hydrochloride
|
EGFR tyrosine kinase inhibitor |
€70.00 |
|
1393
|
Gefitinib
|
EGFR tyrosine kinase inhibitor |
€70.00 |
|
1394
|
Imatinib mesylate
|
Bcr-Abl, c-KIT and PDGFR kinase inhibitor |
€60.00 |
|
1395
|
Lapatinib ditosylate
|
EGFR and ErbB-2/HER2 tyrosine kinase inhibitor |
€80.00 |
|
1398
|
Sunitinib malate
|
Multi-targeted receptor tyrosine kinase inhibitor |
€80.00 |
|
1411
|
Vandetanib
|
VEGFR and EGFR tyrosine kinase inhibitor |
€50.00 |
|
1414
|
AG 013736
|
PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor |
€50.00 |
|
1415
|
CT 53518
|
PDGFR, c-KIT and FLT3 tyrosine kinase inhibitor |
€70.00 |
|
1419
|
AB 1010
|
PDGFR, c-KIT and FGFR3 tyrosine kinase inhibitor |
€70.00 |
|
1420
|
Pazopanib hydrochloride
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€60.00 |
|
1433
|
CI 1033
|
EGFR tyrosine kinase inhibitor |
€60.00 |
|
1461
|
Cediranib
|
VEGFR tyrosine kinase inhibitor |
€70.00 |
|
1506
|
WZ 4002
|
EGFR kinase inhibitor (T790M specific) |
€70.00 |
|
1526
|
Neratinib
|
EGFR and ErbB-2/HER2 tyrosine kinase inhibitor |
€80.00 |
|
1544
|
BIBW 2992
|
EGFR and ErbB-2/HER2 tyrosine kinase inhibitor |
€50.00 |
|
1547
|
OSI 930
|
c-Kit and VEGFR2 tyrosine kinase inhibitor |
€90.00 |
|
1581
|
SU 11274
|
ATP-competitive inhibitor of c-MET |
€90.00 |
|
1582
|
Foretinib
|
c-MET and VEGFR2 tyrosine kinase inhibitor |
€90.00 |
|
1583
|
PF 04217903 mesylate
|
c-MET tyrosine kinase Inhibitor |
€80.00 |
|
1632
|
OSI 420
|
EGFR tyrosine kinase inhibitor |
€90.00 |
|
1637
|
Vatalanib
|
VEGFR tyrosine kinase inhibitor |
€75.00 |
|
1638
|
ABT 869
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€85.00 |
|
1653
|
AEE 788
|
EGFR, ErbB2 and VEGFR tyrosine kinase inhibitor |
€80.00 |
|
1660
|
Crizotinib
|
c-MET Inhibitor; NPM-ALK inhibitor |
€70.00 |
|
1662
|
CP 547632
|
VEGFR2 tyrosine kinase inhibitor |
€70.00 |
|
1665
|
Pelitinib
|
EGFR tyrosine kinase inhibitor |
€90.00 |
|
1678
|
Regorafenib
|
Multi-kinase RTK inhibitor |
€70.00 |
|
1696
|
Quizartinib dihydrochloride
|
FLT3 inhibitor |
€90.00 |
|
1717
|
Tivozanib
|
VEGFR1, 2, and 3 tyrosine kinase inhibitor |
€80.00 |
|
1760
|
EGFR Inhibitor [879127-07-8]
|
Highly selective EGFR tyrosine kinase inhibitor |
€120.00 |
|
1768
|
AMG 706
|
Multiple receptor tyrosine kinase inhibitor |
€105.00 |
|
1838
|
ARQ 197
|
c-MET tyrosine kinase Inhibitor |
€90.00 |
|
1850
|
BMS 540215
|
Inhibitor of VEGFR (subtype 2 and 3 selective) |
€110.00 |
|
1864
|
Brivanib alaninate
|
Prodrug of BMS 540215; Inhibitor of VEGF |
€90.00 |
|
1891
|
SU 6668
|
Inhibitor of RTK targeting PDGFR, VEGF and FGFR |
€100.00 |
|
1914
|
SGX 523
|
ATP-competitive inhibitor of c-MET |
€120.00 |
|
1916
|
AMG 208
|
Inhibitor of c-MET receptor tyrosine kinase (RTK) |
€95.00 |
|
1942
|
E 3810 dihydrochloride
|
Dual VEGFR/FGFR tyrosine kinase inhibitor |
€90.00 |
|
1959
|
Golvatinib
|
Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2 |
€90.00 |
|
1963
|
LY 573636
|
Anti-tumor agent; causes growth arrest and apoptosis |
€80.00 |
|
1978
|
ZM 323881 hydrochloride
|
Inhibitor of VEGFR2 |
€105.00 |
|
1986
|
AST 1306 tosylate
|
ErbB2 and EGFR inhibitor |
€90.00 |
|
1667
|
SU 5402
|
Fibroblast growth factor receptor (FGFR) inhibitor |
€60.00 |
|
2368
|
Amuvatinib
|
RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met |
€105.00 |
|
2501
|
Pexidartinib
|
Mutil-targeted RTK inhibitor of CSF1R, c-Kit, and FLT3 |
€60.00 |
|
2553
|
LY 2801653
|
Orally bioavailable multi-kinase inhibitor with potent activity against c-MET |
€120.00 |
|
2648
|
Nintedanib
|
RTK inhibitor with antiangiogenic and antineoplastic activities |
€70.00 |
|
2667
|
RET Inhibitor 2667
|
Potent RTK inhibitor with activity against wild-type RET and its mutants |
€125.00 |
|
2680
|
EAI045
|
Allosteric EGFR inhibitor (L858R/T790M-specific) |
€105.00 |
|
2767
|
SU11652
|
Multi-targeted receptor tyrosine kinase inhibitor |
€140.00 |
|
2849
|
Apatinib
|
Inhibitor of VEGFR2 |
€120.00 |
|
2865
|
NVP-ACC789
|
Inhibitor of VEGFR2 |
€90.00 |
|
2837
|
BMS 605541
|
Potent, selective, orally active, and ATP-competitive VEGFR2 inhibitor |
€90.00 |
|
3165
|
Lenvatinib
|
Multi-targeted receptor tyrosine kinase inhibitor |
€70.00 |
|
3423
|
Capmatinib
|
Highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor |
€80.00 |
|
3338
|
Taxifolin
|
Inhibitor of VEGFR2 |
€50.00 |
|
3624
|
Toceranib phosphate
|
Multi-targeted receptor tyrosine kinase inhibitor |
€60.00 |
|
3864
|
Volitinib dihydrochloride
|
ATP-competitive small molecule c-Met kinase inhibitor |
Inquire |
|
3945
|
AMG-337
|
Potent and exquisitely selective inhibitor of wild-type and some mutant forms of c-Met |
Inquire |
|
3946
|
Altiratinib
|
Balanced inhibitor for MET, TIE2 (TEK), and VEGFR2 (KDR) kinases |
Inquire |
|
3969
|
Crenolanib
|
Selective small molecule inhibitor of PDGFRα, PDGFRβ and FLT3. |
Inquire |
|
3975
|
MGCD265 dihydrochloride
|
Orally active, potent MET/SMO dual inhibitor |
€130.00 |
|
3998
|
MGCD516
|
Orally bioavailable receptor tyrosine kinase (RTK) inhibitor |
Inquire |
|
4040
|
BMS-777607
|
potent, selective and orally bioavailable c-Met inhibitor |
Inquire |
|
4073
|
CYC-116
|
Aurora kinases A & B and VEGFR2 inhibitor |
Inquire |